Feb 26 |
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
|
Feb 7 |
Jefferies cuts Rallybio to hold, cites lack of near-term catalysts
|
Feb 6 |
Rallybio shares jump 13% on restructuring, cash runway extension
|
Feb 6 |
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
|
Jan 4 |
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
|
Dec 20 |
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
|
Dec 9 |
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
|
Nov 28 |
Rallybio posts early Phase 1 data for lead candidate in bleeding disorder
|
Nov 28 |
Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
|
Nov 9 |
Rallybio GAAP EPS of -$0.45
|